US high court says biosimilar sponsors do not have to wait until after FDA approval to start countdown clock for marketing, but patent litigation may impede launches.
The US Supreme Court has given bosimilar sponsors the opportunity to launch immediately after approval but they still could be delayed by patent battles and strategic considerations.
In its unanimous June 12 opinion in Sandoz Inc. v. Amgen Inc., the court concluded that...
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Swiss major confident that new oncology drugs will fill revenue gap.
An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
